Nevertheless, in a large scale study of 150 small molecule inhibitors in a panel of 28 early passage melanoma lines[39] analysis showed that the most effective drug combination for BRAF-mutant lines was that of vemurafenib, EGFR, and AKT inhibitors, which was cytotoxic even in lines with primary resistance to vemurafenib or in lines selected for resistance to vemurafenib. The gene discussed is BRAF; the disease is melanoma.